Cargando…

Discovery of a Potent Candidate for RET-Specific Non-Small-Cell Lung Cancer—A Combined In Silico and In Vitro Strategy

Rearranged during transfection (RET) is a tyrosine kinase oncogenic receptor, activated in several cancers including non-small-cell lung cancer (NSCLC). Multiple kinase inhibitors vandetanib and cabozantinib are commonly used in the treatment of RET-positive NSCLC. However, specificity, toxicity, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramesh, Priyanka, Shin, Woong-Hee, Veerappapillai, Shanthi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619101/ https://www.ncbi.nlm.nih.gov/pubmed/34834190 http://dx.doi.org/10.3390/pharmaceutics13111775

Ejemplares similares

Designing Novel Compounds for the Treatment and Management of RET-Positive Non-Small Cell Lung Cancer—Fragment Based Drug Design Strategy
por: Ramesh, Priyanka, et al.
Publicado: (2022)

Machine learning driven drug repurposing strategy for identification of potential RET inhibitors against non-small cell lung cancer
por: Ramesh, Priyanka, et al.
Publicado: (2022)

Gene expression profiling of corona virus microarray datasets to identify crucial targets in COVID-19 patients
por: Ramesh, Priyanka, et al.
Publicado: (2021)

A review on recent advancements in diagnosis and classification of cancers using artificial intelligence
por: Ramesh, Priyanka, et al.
Publicado: (2020)

Envelope Glycoprotein based multi-epitope vaccine against a co-infection of Human Herpesvirus 5 and Human Herpesvirus 6 using in silico strategies
por: Gandhamaneni, Bharath Sai, et al.
Publicado: (2022)

The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity
por: Newton, Rebecca, et al.
Publicado: (2016)

Design of a potential Sema4A-based multi-epitope vaccine to combat triple-negative breast cancer: an immunoinformatic approach
por: Paranthaman, Priyanga, et al.
Publicado: (2023)

In Silico Discovery of Candidate Drugs against Covid-19
por: Cava, Claudia, et al.
Publicado: (2020)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

In Silico Strategies in Tuberculosis Drug Discovery
por: Macalino, Stephani Joy Y., et al.
Publicado: (2020)

Novel Soloxolone Amides as Potent Anti-Glioblastoma Candidates: Design, Synthesis, In Silico Analysis and Biological Activities In Vitro and In Vivo
por: Markov, Andrey V., et al.
Publicado: (2022)

Therapeutic strategies in RET gene rearranged non-small cell lung cancer
por: Drusbosky, Leylah M., et al.
Publicado: (2021)

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018)

Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening
por: Elkamhawy, Ahmed, et al.
Publicado: (2021)

In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α
por: Singh, Kriti, et al.
Publicado: (2015)

Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review
por: Takeuchi, Kengo
Publicado: (2019)

Discovery of DNA dyes Hoechst 34580 and 33342 as good candidates for inhibiting amyloid beta formation: in silico and in vitro study
por: Thai, Nguyen Quoc, et al.
Publicado: (2016)

Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design
por: Zhou, Yunjiang, et al.
Publicado: (2019)

In Silico discovery of aptamers with an enhanced library design strategy
por: Chen, Long, et al.
Publicado: (2023)

Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity
por: Aguiar, Anna C.C., et al.
Publicado: (2018)

In Silico Discovery of Novel Potent Antioxidants on the Basis of Pulvinic Acid and Coumarine Derivatives and Their Experimental Evaluation
por: Martinčič, Rok, et al.
Publicado: (2015)

In Silico Discovery and Subsequent Characterization of Potent 4R-Tauopathy Positron Emission Tomography Radiotracers
por: Graham, Thomas J. A., et al.
Publicado: (2023)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021)

RET Fusion Genes in Korean Non-Small Cell Lung Cancer
por: Yoo, Seung Soo, et al.
Publicado: (2013)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

In silico prioritisation of candidate genes for prokaryotic gene function discovery: an application of phylogenetic profiles
por: Lin, Frank PY, et al.
Publicado: (2009)

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

Discovery of Potent and Specific Dihydroisoxazole Inhibitors of Human Transglutaminase 2
por: Klöck, Cornelius, et al.
Publicado: (2014)

Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization
por: Schmutzler, Brian S, et al.
Publicado: (2011)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Elucidating the Role of Santalol as a Potent Inhibitor of Tyrosinase: In Vitro and In Silico Approaches
por: Ali, Nabeel, et al.
Publicado: (2022)

Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery
por: Macalino, Stephani Joy Y., et al.
Publicado: (2018)

In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery
por: de Souza Neto, Lauro Ribeiro, et al.
Publicado: (2020)

Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2017)

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
por: Takeuchi, Shinji, et al.
Publicado: (2021)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cb92tt3hqbju3ol6emjec3uq9o